[Characteristics of the effect of myelosan on the immune status of patients with chronic myeloid leukemia].
Guseva
S A
SA
D000276:Adjuvants, Immunologic; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002066:Busulfan / Q000627:therapeutic use*; D006801:Humans; D007109:Immunity / Q000187:drug effects* / Q000276:immunology; D007136:Immunoglobulins / Q000032:analysis; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy* / Q000209:etiology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology; D007958:Leukocyte Count / Q000187:drug effects; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology
D000276:Adjuvants, Immunologic; D007136:Immunoglobulins; D002066:Busulfan
Osobennosti deĭstviia mielosana na immunnyĭ status bol'nykh khronicheskim mieloleĭkozom.